Inylta 5mg, containing the active ingredient Axitinib, is a tyrosine kinase inhibitor used to deal with advanced kidney cancer (renal cell carcinoma). This drug can harm a fetus, so inform your doctor if you are pregnant or planning to conceive. Both men and women should use birth control during treatment and for one week after the last dose. Do not breastfeed during treatment, as it may affect the baby's development.

It is not advisable for use in children and adolescents under 18 years old. Urgently contact your healthcare provider if you develop symptoms like arrhythmia, chest pain, or a persistent cough. Your doctor may require regular monitoring of your white blood cells, platelets, blood sugar, electrolytes, and kidney function to avert complications. Additionally, report any digestive symptoms such as diarrhoea, nausea, vomiting, or constipation to your healthcare provider without delay. Inlyta 5mg price varies by retailer and location. Buy Inlyta 5mg Tablet online through various platforms lie MrMed at affordable prices.

Inlyta 5mg uses are: 

• Targets specific enzymes to prevent the growth and spread of cancer cells.

• Aids in reducing symptoms associated with advanced kidney cancer, improving the patient's quality of life.

Axitinib is a tyrosine kinase inhibitor. It disrupts the growth of blood vessels within cancer cells and targets receptor tyrosine kinases, a type of protein crucial for cell signalling. By interfering with these pathways, it effectively halts the proliferation and spread of cancer cells, contributing to the containment of the disease

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Inylta 5mg tablet and reduce effectiveness by causing undesirable side effects.

• Keep Inlyta 5mg tablets in their original packaging and store them at room temperature, ideally between 20°C and 25°C.
• Ensure the medication is kept out of the reach of children at all times.

Your doctor will decide the dose and duration of Inylta 5mg tablet based on the disease condition. Always take this medicine as prescribed by your doctor. The recommended starting oral dose is 5 mg twice daily. Take the tablet at the same time every day, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next Inlyta 5mg tablet dosage at the scheduled time. Do not take a double dose to make up for a forgotten dose.

Inlyta 5mg side effects of the drug range from the most common ones to those you should take a closer look at. Here is what you need to know:

Common:

• Kidney issues and dehydration
• Sore throat and loss of appetite
• Joint pain and weight loss
• Skin reactions, including itching, redness, and hair loss

Serious:

• Severe fatigue and swelling
• Chest pain or pressure, especially radiating to arms, back, neck, or jaw
• Shortness of breath and difficulty speaking
• Significant bleeding, such as black stools or bloody cough

• Inylta 5mg may cause dizziness and weakness, so avoid driving or operating heavy machinery if affected.

• Do not consume grapefruit or grapefruit juice, as it can increase the drug's plasma concentration.

• Some formulations may contain lactose, which may cause bloating or abdominal pain in lactose-intolerant patients. Inform your doctor if you have lactose intolerance.

• In case of severe diarrhea, avoid high-fiber foods and ensure adequate fluid intake.

1. Pfizer Labs, Electronic Medicines Compendium(EMC), [Revised on Mar 2021] [Accessed on 23rd March 2023], https://www.medicines.org.uk/emc/files/pil.4325.pdf
2. Pfizer, Fact sheet, [Revised on Sep 2012] [Accessed on 23rd March 2023], https://cdn.pfizer.com/pfizercom/news/esmo/renal_cell_carcinoma_fact_sheet.pdf
3. Annex I summary of Product Characteristics - European Medicines Agency. Available at:https://www.ema.europa.eu/en/documents/product-information/inlyta-epar-product-information_en.pdf (Accessed on March 25, 2023).
4. Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.